Neurological immune reconstitution inflammatory response: Riding the tide of immune recovery

Current Opinion in Neurology

Volumn 28, Issue 3, 2015, Pages 295-301

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cryptococcal meningitis; HIV; immune reconstitution inflammatory syndrome (IRIS); JC virus; progressive multifocal leukoencephalopathy (PML)

Indexed keywords

ANTIFUNGAL AGENT; NATALIZUMAB;

CRYPTOCOCCAL MENINGITIS; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MORBIDITY; MORTALITY; NEUROIMAGING; OUTCOME ASSESSMENT; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; TREATMENT OUTCOME; COMPLICATION; IMMUNE SYSTEM; IMMUNOLOGY; NERVOUS SYSTEM DISEASES; PATHOLOGY; PATHOPHYSIOLOGY;

HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; NERVOUS SYSTEM DISEASES;

EID: 84929462054     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000200     Document Type: Review

References (56)

1. Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens. AJNR Am J Neuroradiol 2013; 34:1308-1318.
2. Laureillard D, Marcy O, Madec Y, et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013; 27:2577-2586.
3. Lagier JC, Raoult D. Immune reconstitution inflammatory syndrome associated with bacterial infections. Expert Opin Drug Saf 2014; 13:341-350.
4. Luetkemeyer AF, Kendall MA, Nyirenda M, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr 2014; 65:423-428.
5. Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 2013; 34:1297-1307.
6. Iro MA, Kirkham FJ, Macdonald JH, et al. Varicella zoster virus central nervous system immune reconstitution inflammatory syndrome presenting in a child. Pediatr Infect Dis J 2013; 32:1283-1284.
7. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
8. Mateen FJ, Nath A. Central nervous system-immune reconstitution inflammatory syndrome in resource-limited settings: current burden and future needs. AIDS 2012; 26:1851-1855.
9. Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424-433.
10. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS 2014; 28:2461-2473.
11. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014; 75:108-115.
12. Clifford DB. Progressive multifocal leukoencephalopathy therapy. J Neurovirol 2014.
13. Gasnault J, Costagliola D, Hendel-Chavez H, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 2011; 6:e20967.
14. Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19:351-358.
15. Vermersch PD, Kappos LM, Gold RM, et al. Clinical outcomes of natalizumabassociated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697-1704.
16. Huang D, Cossoy M, Li M, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. AnnNeurol 2007; 62:34-39.
17. Martin-Blondel G, Bauer J, Cuvinciuc V, et al. In situ evidence of JC virus control by CD8\+ T cells in PML-IRIS during HIV infection. Neurology 2013; 81:964-970.
18. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012; 123:235-245.
19. Wuthrich C, Popescu BF, Gheuens S, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol 2013; 72:1043-1051.
20. Schippling S, Kempf C, Buchele F, et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 2013; 74:622-626.
21. Dang X, Vidal JE, Oliveira AC, et al. JC virus granule cell neuronopathy is associated with VP1C terminus mutants. J General Virol 2012; 93:175-183.
22. Dang L, Dang X, Koralnik IJ, Todd PK. JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. JAMA Neurol 2014; 71:487-489.
23. Lach B, Connolly B, Wuthrich C, Koralnik IJ. Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis. Neuropathology 2014; 34:39-44.
24. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72:779-787.
25. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19:1826-1840.
26. Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? J Neurol Neurosurg Psychiatry 2013; 84:1176-1177.
27. Khoury MN, Alsop DC, Agnihotri SP, et al. Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 2014; 75:659-669.
28. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78:1390-1393.
29. Gheuens S, Ngo L, Wang X, et al. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 2012; 79:1041-1048.
30. Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84:1068-1074.
31. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Trans Neurol 2014; 1:755-764.
32. Khatri B, Fox R, Koo A, et al. The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study (poster presented at 23rd Congress of the European Committee for Treatment and Research in Multiple Scerosis-ECTRIMS). Mult Scler 2007; 13:S172.
33. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 2012; 79:2258-2264.
34. Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014; 370:486-488.
35. Sospedra M, Schippling S, Yousef S, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 2014; 59:1588-1592.
36. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487-2498.
37. McKenney J, Smith RM, Chiller TM, et al. Prevalence and correlates of cryptococcal antigen positivity among AIDS patients-United States, 1986-2012. MMWR Morb Mortal Weekly Rep 2014; 63:585-587.
38. Jarvis JN, Govender N, Chiller T, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resourcelimited settings: a proposed algorithm for clinical implementation. J Int Assoc Phys AIDS Care 2012; 11:374-379.
39. Meyer AC, Kendi CK, Penner JA, et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health 2013; 18:495-503.
40. Vijayan T, Chiller T, Klausner JD. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs 2013; 45:16-20.
41. Alemu AS, Kempker RR, Tenna A, et al. High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One 2013; 8:e58377.
42. Gates-Hollingsworth MA, Kozel TR. Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen. Clin Vaccine Immunol 2013; 20:634-635.
43. Rugemalila J, Maro VP, Kapanda G, et al. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-ofcare lateral flow assay. Trop Med Int Health 2013; 18:1075-1079.
44. Escandon P, Lizarazo J, Agudelo CI, et al. Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia. Med Mycol 2013; 51: 765-768.
45. Chang CC, Lim A, Omarjee S, et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208:898-906.
46. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202: 962-970.
47. Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis 2014; 209:74-82.
48. Haynes BC, Skowyra ML, Spencer SJ, et al. Toward an integrated model of capsule regulation in Cryptococcus neoformans. PLoS Pathog 2011; 7:e1002411.
49. Longley N, Harrison TS, Jarvis JN. Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis 2013; 26:26-34.
50. Manji H, Jager HR, Winston A. HIV, dementia and antiretroviral drugs: 30 years of an epidemic. J Neurol Neurosurg Psychiatry 2013; 84:1126-1137.
51. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-645.
52. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67:383-388.
53. Roh D, Glenn MD, Petito CK, et al. Reversible severe encephalitis and word deafness following rapid immune reconstitution in AIDS: a case report. J Neurovirol 2013; 19:190-193.
54. Costello DJ, Gonzalez RG, Frosch MP. Case 18-2011: a 35-year-old HIVpositive woman with headache and altered mental status. N Engl JMed 2011; 364:2343-2352.
55. Gray F, Lescure FX, Adle-Biassette H, et al. Encephalitis with infiltration by CD8\+ lymphocytes in hiv patients receiving combination antiretroviral treatment. Brain Pathol 2013; 23:525-533.
56. Johnson TP, Patel K, Johnson KR, et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA 2013; 110:13588-13593.